Gujarat Terce Laboratories Limited · BSE:GUJTERC
Gujarat Terce Laboratories — Q4 FY25 Earnings Presentation
9 slides from Gujarat Terce Laboratories's earnings presentation, May 26, 2025
Slide 1: BSE cover letter: Investors Presentation for quarter ended March 31, 2025
GUJARAT TERCE LABORATORIES LIMITED Date: 26/05/2025 To, Scrip Code: 524314 BSE Limited Security ID:GUJTERC Corporate Relation Department, ISIN: INE499G01013 Phiroze]eejeebhoy Towers, Dalai Streets, Mumbai 400001, Maharashtra, India DearSir/Ma;iam, Sub: Investors Presentation for quarter ended on Mar
Slide 2: Q4 FY25 Financial Results & Business Update
A GUJARAT TERCE LABORATORIES LIMITED A Q4 FY25 | FINANCIAL RESULTS & BUSINESS UPDATE
Slide 3: Safe Harbour
SAFE HARBOUR THIS PRESENTATION CONTAINS CERTAIN FORWARD-LOOKING STATEMENTS CONCERNING OUR FUTURE BUSINESS PROSPECTS AND BUSINESS PROFITABILITY, WHICH ARE SUBJECT TO SEVERAL RISKS AND UNCERTAINTIES & THE ACTUAL RESULTS COULD MATERIALLY DIFFER FROM THOSE IN SUCH FORWARD-LOOKING STATEMENTS. THE RISKS A
Slide 4: Performance Highlights
PERFORMANCE HIGHLIGHTS & (INR lacs) REVENUE EBIDTA NET PROFIT | PCPM Q4-FY25 Q4-FY24 Q4-FY25 Q4-FY24 Q4-FY25 Q4-FY24 } Q4-FY25 Q4-FY24 1232.44 1220.71 113.94 108.61 -339.14 54.34 } 2.57 2.28 | 1% 5% 724% | 12.82% Growth Increase Decrease } Increase EARNINGS PER SHARE EBIDTA MARGIN ROCE .. EY@5 FY24
Slide 5: Profit & Loss Summary
PROFIT & LOSS SUMMARY — (INR lacs) Revente 1232.44 1220.71 1% 5019.52 4797.47 4.63% EBITDA 113.94 108.61 5% 419.04 158.77 164 % PBT 96.83 84.39 15 % 339.04 54.39 523.35% Current Tax 16.36 16.36 Deferred Tax 77.90 30.05 78.84 30.05 Provision for tax of earlier years under vivad se 34171 Vishwaas Sche
Slide 6: Management Commentary
MANAGEMENT COMMENTARY A—— Dear Shareholders, "Committed A ] I FY 25 has been a landmark year in the journey of Gujarat Terce Laboratories Limited — one where long-term to building ) a®- vision met disciplined execution. sustalnablé: high- We are proud to share that for the first time in our history,
Slide 7: Management Commentary: Core Business Improvements
MANAGEMENT COMMENTARY —— Core Business Improvements Our focus on operational efficiency and financial discipline translated into tangible gains: o® e Brand-wise strategic focus across Paediatrics, Gynaecology, and Consulting Physician segments led to robust performance in key brands like Acolate, Te
Slide 8: Management Commentary: Regulatory Update and Looking Ahead
MANAGEMENT COMMENTARY A—— Regulatory Update: Vivad Se Vishwas Scheme As part of our commitment to resolve past matters, the company opted for the Vivad Se Vishwas scheme to o® settle tax demands related to FY 2010-11, FY 2011-12, FY 2012-13, FY 2013-14. This step helped in: * Close long-pending liti
Slide 9: Thank You / About the Company
ABOUT THE COMPANY CUIARAT TERCE Gujarat Terce has over three decades of experience in manufacturing and marketing branded generics to provide the general public with accessible healthcare. COMPASSION & EXCELLENCE * We have an extensive basket of 50 Brands (125 products) with a portfolio contributing
Gujarat Terce Laboratories — Q4 FY25 Earnings Presentation on 6ix